Decision: Favourable

Study Title:

TRIO045/LidERA : A phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of adjuvant giredestrant compared with physician’s choice of adjuvant endocrine monotherapy in patients with estrogen receptor-positive, HER2-negati

  • NREC Code:

    21-NREC-CT-023

  • Decision:

    Favourable

  • Meeting Date:

    21/06/2021

  • Study Type:

    CT application

  • Principal Investigator:

    Prof Janice Walshe

  • PI Institution:

    St Vincent's University Hospital

  • Sponsor:

    F. Hoffman La Roche Ltd

Scroll to Top
Skip to content